Xueba’s medical black technology system

Chapter 241: Speculation triggered by the article
Zhou Jun was not the only one who read Lu Liang’s article about Alzheimer’s disease.

Zhang Zichun was bored and scrolling through something. He has now completed his graduation test, and the data results are also very beautiful.

This made Zhang Zichun feel lucky that the original choice of changing the topic from liraglutide to metformin was extremely correct.

With excellent data, the graduation thesis will naturally be easier to write. He has now completed the thesis and is just waiting to take it to the blind review.

In a sense, Zhang Zichun has become the most leisurely person in their research group.

"Let's play with the phone."

Zhang Zichun opened something while thinking, wanting to see if there were any interesting topics recently.

"How to evaluate it? Idol trainee Ji Taimei's latest album "Two and a Half Years" has been released. In just two and a half hours, 150 million copies have been sold."

Nowadays, there are almost all kinds of stuff on the Internet.

Zhang Zichun shook his head and looked down.

"How to evaluate the health anxiety among young people today who stay up all night drinking wolfberry."

Zhang Zichun kept scrolling down to refresh something, and as Zhang Zichun refreshed, a question came into Zhang Zichun's eyes.

When he saw this question, Zhang Zichun's fingers couldn't help but paused.

The question is titled "What do you think of the review "Research Progress of Antibodies Targeting Different Targets of Amyloid" published by Yao Daluliang in a core journal?"

When he saw this question, Zhang Zichun couldn't help but frown, and he quickly opened the question.

The person who asked the question on the Internet is a person with the ID name "Machima's Dog".

Below the title is a detailed description of the problem.

“When the subject was checking relevant professional literature recently, he came across this review published by Lu Liang in a core journal.

Lu Liang’s previous research has been focused on cancer. Now he suddenly published a review on Alzheimer’s disease, and the publication time was very recent. This means that Lu Liang is trying to develop Alzheimer’s disease. Disease-related drugs? "

When he saw the description of this problem, Zhang Zichun's heart skipped a beat.

Because he had to answer various professional questions from water friends during his previous live broadcast, Zhang Zichun is different from others. He has a wider range of professional coverage and has a little understanding of all aspects.

So he naturally knew what this amyloid protein was.

Zhang Zichun glanced at the answers to this question. In less than half a day, this question had already received nearly 90 answers.

"First of all, let me state that my research direction is neuroinflammation. Before answering the title question, I took a look at the review."

"It's basically certain that this was not written to enhance your resume. At least it can be judged that Lu Liang has checked a lot of research on Alzheimer's disease."

"Therefore, it is very likely that he is really aiming for a specific drug for Alzheimer's disease this time, and the direction of drug development should be to target amyloid protein."

A self-proclaimed professional in the same research field answered the question below.

“Is it really too difficult to develop a specific drug for Alzheimer’s disease?

Over the years, many pharmaceutical giants have successively launched attacks on Alzheimer's disease, but many of them eventually fell to Alzheimer's disease.

None of them have been successful. All I can say is don’t raise your expectations too high. This time it’s very high. "

A veteran in an industry gave this answer. "To be honest, amyloid protein should not be used as a target. So far, all specific drugs designed to clear amyloid protein deposits outside nerve cells have failed. I think Tau protein is more promising."

"Of course, this is just my superficial understanding. Others may have new ideas."

Regarding this matter, many professionals have given their own answers. Of course, more netizens have gathered together to share the news.

"Zhou Cao, if this is successful, it will definitely benefit many patients, right?"

"I just saw the news not long ago that Eli Lilly's drug development failed. Can this be successful?"

"I've heard that Alzheimer's is more complicated than many cancers."

This topic quickly became a hot search topic and quickly spread to other platforms.

At the same time, Hengrui Pharmaceutical.

Sun Piao frowned at the news.

For pharmaceutical companies like them, Alzheimer's disease can be described as a treasure. Which pharmaceutical company can be the first to conquer Alzheimer's disease and develop a specific drug for Alzheimer's disease.

Then you can make an extremely terrifying profit.

This is why these pharmaceutical companies are trying their best. After failing again and again, they still continue to invest money in developing drugs.

Therefore, after the topic of Alzheimer's disease became a hot search topic, Sun Piao immediately noticed the movement.

"Alzheimer's disease, isn't it? Are you serious?"

After a long time, Sun Piao put down the phone and couldn't help but sigh.

Not long ago, he saw that Eli Lilly and Company announced that it had failed to develop a specific drug for Alzheimer's disease. However, it was not long before he received such a piece of bombshell news.

Then, Sun Piao looked at Zhao Rui and asked, "Old Zhao, what do you think, is it really possible for him to develop a specific drug for Alzheimer's disease?"

Regarding this matter, Zhao Rui could only smile bitterly and shake his head: "Mr. Sun, do you want to listen to the truth?"

"Otherwise, this matter has nothing to do with the company, so feel free to say it."

Zhao Rui sighed: "To be honest, Mr. Sun, I'm not sure about this matter either."

Sun Piao was a little surprised: "Old Zhao, aren't you sure?"

Zhao Rui nodded: "Mr. Sun, you think Lu Liang is possible, but pharmaceutical companies with top technologies such as Pfizer, Roche, Merck, and AstraZeneca have all failed, and they have failed miserably."

"But you say it's impossible. Everything Lu Liang did before cannot be measured by common sense. Maybe he can create a miracle again this time."

"So, I'm not sure about this matter. Any situation could happen."

After listening to Zhao Rui's analysis, Sun Piao nodded. What Zhao Rui said was not unreasonable. No one knew what the outcome would be until the end.

However, Sun Piao seemed to have thought of something, and he said, "But this time, many people have great expectations for him."

Zhao Rui nodded: "This is not a good thing. If it succeeds, it will be fine. If it fails, someone with good intentions will probably use it to make a big fuss."

"Then we can only see the final result." Sun Piao shook his head and said.

(End of this chapter)